WO1997017966A1 - Hemoregulatory compounds - Google Patents

Hemoregulatory compounds Download PDF

Info

Publication number
WO1997017966A1
WO1997017966A1 PCT/US1996/018250 US9618250W WO9717966A1 WO 1997017966 A1 WO1997017966 A1 WO 1997017966A1 US 9618250 W US9618250 W US 9618250W WO 9717966 A1 WO9717966 A1 WO 9717966A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
independently
denotes
hydrogen
integer
Prior art date
Application number
PCT/US1996/018250
Other languages
French (fr)
Inventor
Pradip Kumar Bhatnagar
Dirk Andries Heerding
Michael Hartmann
Johann Hiebl
Peter Kremminger
Franz Rovenszky
Original Assignee
Smithkline Beecham Corporation
Nycomed Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Nycomed Austria Gmbh filed Critical Smithkline Beecham Corporation
Priority to JP9519064A priority Critical patent/JP2000502049A/en
Priority to EP96940440A priority patent/EP0877611A4/en
Priority to US09/068,640 priority patent/US6077856A/en
Publication of WO1997017966A1 publication Critical patent/WO1997017966A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to novel compounds which have hemoregulatory activities and can be used to stimulate haematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.
  • the haematopoietic system is a life-long cell renewal process whereby a defined stem cell population gives rise to a larger population of mature, differentiated blood cells (Dexter TM. Stem cells in normal growth and disease, Br Med J 1987; 195: 1 192-1 194) of at least nine different cell lineages (erythrocytes, platelets, eosinophils, basophils, neutrophils, monocytes/macrophages, osteoclastes and lymphocytes) (Metcalf D. The Molecular Control of Blood Cells, 1988; Harvard University Press, Cambridge, MA). The stem cells are also ultimately responsible for regenerating the bone marrow following treatment with cytotoxic agents or following bone marrow transplantation.
  • the risk of infection is directly related to the degree of myelosuppression as measured by the severity and duration of neutropenia (Brody GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infections with acute leukemia. Ann In Med 1965; 64:328-334).
  • the control of haematopoiesis involves the interplay of a variety of cytokines and growth factors during various stages of the haematopoietic cascade, including early pluripotent stem cells and mature circulating effector cells.
  • G-CSF granulocyte colony stimulating factor
  • GM-CSF granulocyte- macrophage stimulating factor
  • M-CSF macrophage-colony stimulating factor
  • G-CSF granulocyte colony stimulating factor
  • interleukines which have overlapping, additive and synergistic actions which play major roles in host defence. Mechanistically, this is accomplished by enhancing the production of granulocytes and macrophages, as well as by the activation of effector cell functions (Moore MAS. Haematopoietic growth factor interactions: in vitro and in vivo preclinical evaluation. Cancer Surveys 1990; 9:7-80).
  • These co-ordinated activities support optimal host defences which are necessary for fighting bacterial, viral and fungal infections.
  • G-, GM- and/or M-CSF may reduce the duration of neutropenia, accelerate myeloid recovery and reduce neutropenia-associated infections and other infectious complications in patients with malignancies who are receiving cytotoxic chemotherapy or in high infectious-risk patients following bone marrow transplantation (Steward WP. Granulocyte and granulocyte-macrophage colony stimulating factors, Lancet 1993; 342: 153-157 and Munn DH, Cheung NKV. Preclinical and clinical studies of macrophage colony- stimulating factor. Semin Oncol 1992; 19:395-407).
  • This invention comprises compounds, hereinafter represented as Formula (I), which have hemoregulatory activities and can be used to stimulate haematopoiesis and in the prevention and treatment of bacterial, viral and fungal diseases
  • These compounds are useful in the restoration of leukocytes in patients with lowered cell counts resulting from a variety of clinical situations, such as surgical induced myelosuppression, AIDS, ARDS, congenital myelodysplacis, bone marrow and organ transplants, in the protection of patients with leukopenia from infection, in the treatment of severely burned patients and in the amelioration of the myelosuppression observed with some cell-cycle specific antiviral agents and in the treatment of infections in patients who have had bone marrow transplants, especially those with graft versus host disease, in the treatment of tuberculosis and in the treatment of fevers of unknown origin in humans and animals
  • the compounds are also useful in the treatment and prevention of viral, fungal and bacterial diseases, particularly Candida, Herpes and hepatitis in both immunosuppressed and "normal" subjects
  • This invention is also a pharmaceutical composition, which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.
  • This invention further constitutes a method for stimulating the myelopoietic system of an animal, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).
  • This invention also constitutes a method for preventing and treating viral, fungal and bacterial infections including sepsis, in immunosuppressed and normal animals, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).
  • Aj equals A2 and denotes a group Z-(CH2)k-(NR"')q, wherein Z is a 4 - 10 membered mono- or bicyclic heterocyclic ring system containing up to four heteroatoms N, O, S in the ring in which at least one heteroatom is N, and wherein the ring is substituted or unsubstituted by one or two Cj ⁇ alkyl, F, Cl, Br, I, Cj.4 alkoxy, (CH2) m R4, oxo, oxime, O-C]_4alkyloxime, hydroxy, N(R )2, acylamino or aminoacyl groups, 8, 9, 10 membered monocyclic ring systems being excluded; R and R are the same and are independently hydrogen, Cj_4alkylC(O)R4, C ⁇ _ 4alkyl or R' and R" are benzyl which is optionally substituted by one or two Cj ⁇ alkyl, C] 4 alkoxy, F, Cl,
  • B ⁇ equals B2 and denotes halogen, -(CH2) m -CN, -(CH2) m +l-R ⁇ .
  • R2 denotes - OR 3 , -N(R 3 ) 2 , - SR 3 ;
  • R 3 is independently hydrogen, C ⁇ -C4-alkyl or benzyl;
  • m is independently an integer from 0 to 4;
  • Ci C2 and denotes halogen, -(CH2) n -CN, -(CH2) n +l-R > -(CH 2 ) n -R 5 , -(CH 2 ) n -COR4 or -(CH 2 ) n -COR5;
  • R 4 independently denotes -OR 5 , -N(R 5 ) 2 , - SR 5 ;
  • R 5 independently is hydrogen, Cj-C4-alkyl or benzyl;
  • n is independently an integer from 0 to 4;
  • D is (CH2)i, in which up to two carbons are optionally gem-substituted by R 6 and R 7 ;
  • R6 and R 7 are independently C ⁇ _4alkyl, C2-4alkenyI, C2_4alkynyl; all of which may be substituted by one or two Cj ⁇ alkyl, OH, F, Cl, Br, I, N(Rg)2, (Rs)2 C(O)-, -(CH 2 ) n R 9 , -(CH 2 ) n R 8 , -(CH) 2 ) n COR9 or -(CH 2 ) n C(0)R8; or R 6 and R 7 are F, Cl, or Br; or R" and R 7 may together form a cyclic or heterocyclic ring of Formula (Ia): (CH 2 ) p (CH 2 ) q da)
  • p and q are independently an integer from 0 to3; provided p and q are not both 0;
  • X is O, S, CH 2 or N(R 8 );
  • R 8 is independently hydrogen, Cj_4-alkyl or benzyl
  • R 9 is independently OR 8 , N(R 8 ) 2 or SR 8 ; i is an integer from 3 to 8; and with the proviso that B i is not identical to Cj and B2 is not identical to C2, and pharmaceutically acceptable salts thereof.
  • Z in the above Formula (I) denotes an optionally substituted pyrrolyl, isopyrrolyl, pyrazolyl, isoimidazolyl, triazolyl, iosxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, piperazinyl, triazinyl, morpholinyl, indolyl, indoleninyl, isobenzazolyi, pyrindinyl, ioindazolyl, indoxazinyl, benzoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, pyridopyridinyl, tetrahydroquinolinyl,
  • Possible substituents for Z are C ⁇ _4-alkyl, Cj ⁇ -alkoxy, C ⁇ _4-alkoxy-C ⁇ _4-alkyl, oxo, oxime, O-Cj ⁇ -alkyloxime, hydroxy, amino, C ⁇ _4-aIkylamino, di-C j _4- alkylamino, acylamino and aminoacyl.
  • R3, as well as R 5 denotes hydrogen, methyl, ethyl, propyl, i-propyl, butyl and benzyl.
  • Preferred compounds are those wherein Z is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, tetrahydroquinolinyl, azetidinyl, or pyrrolidinyl;
  • R ⁇ and R are Cj_4alkyl, substituted by C 1.4 alkyl, OH, N(R 8 ) 2 , -(CH 2 ) n R 9 , or -(CH 2 ) n C(O)R 8 ; or R 6 and R 7 may together form a cyclic or heterocyclic ring of Formula (Ia) wherein X is O, S, or CH2; and p and q are 1-3; R 8 is hydrogen or C 1.4 alkyl; and R 9 is OR 8 or
  • More preferred compounds are those wherein Z is 2-pyridinyl, 2-pyrimidinyl, 2-pyrazinyl, 2-pyrrolidon-5-yl, or pyrrolidinyl; R6 and R 7 are Cj_2 alkyl, substituted by C j ⁇ alkyl, OH, N(R )2, or -(CH2) n ; or R ⁇ a °d R 7 may together form a heterocyclic ring of Formula (Ia) wherein X is O; and p and q are 1 or 2; Rg is hydrogen or Cj.4a.kyl; and R 9 is OR 8 , or
  • Preferred substituents for Z are methyl, ethyl, methoxy, methoxy methyl, oxo, oxime, hydroxy, amino, ethylamino or dimethylamino.
  • R' and R" are hydrogen, methyl and ethyl.
  • Alkyl groups may be straight or branched.
  • the compounds of the present invention may contain one ore more asymmetric carbon atoms and may exist in racemic and optically active forms. All the compounds and diastereomers are contemplated to be within the scope of the present compounds.
  • (2S)-2,5-Dihydro-3,6-diethoxyisopro ⁇ ylpyrazine (1 in Scheme 1) is coupled with an appropriate dielectrophile, such as 2 in Scheme 1, using a strong base (such as butyllithium) in a suitable solvent (such as THF) to give 3 in Scheme 1.
  • a strong base such as butyllithium
  • a suitable solvent such as THF
  • Hydrolysis and ring-opening under standard acidic conditions such as diluted HCl
  • a suitable solvent such as dioxane/ethanol
  • an activating agent such as EDC
  • an aprotic polar solvent such as DMF
  • compositions comprising as active ingredient one or more compounds of Formula (I) as herein before defined or physiologically compatible salts thereof, in association with a pharmaceutical carrier or excipient.
  • the compositions according to the invention may be presented for example, in a form suitable for oral, nasal, parenteral or rectal administration.
  • the term "pharmaceutical” includes veterinary applications of the invention. These peptides may be encapsulated, tableted or prepared in an emulsion or syrup for oral administration.
  • Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline and water.
  • Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the amount of solid carrier varies, but, preferably will be between about 20 mg to about 1 g per dosage unit.
  • the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing and filling for hard gelatin capsule forms.
  • Capsules containing one or several active ingredients may be produced, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and filling the mixture into gelatin capsules.
  • Organ specific carrier systems may also be used.
  • compositions of the peptides of this invention or derivatives thereof may be formulated as solutions of lyophilized powders for parenteral administration.
  • Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
  • the liquid formulation is generally a buffered, isotonic, aqueous solution.
  • suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
  • Such formulation is especially suitable for parenteral administration, but may also be used for oral administration and contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxycellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
  • a pulverized powder of the peptides of this invention may be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
  • excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols
  • the pulverized powders may also be compounded with oily preparation, gel, cream or emulsion, buffered or unbuffered, and administered through a transdermal patch.
  • Nasal sprays may be formulated similarly in aqueous solution and packed into spray containers either with an aerosol propeilant or provided with means for manual compression.
  • Dosage units containing the compounds of this invention preferably contain 0.05-50 mg, for example 0.05-5 mg of the compound of Formula (I) or of the salt thereof.
  • a method of stimulation of myelopoiesis which comprises administering an effective amount of a pharmaceutical composition as hereinbefore defined to a subject. No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
  • the biological activity of the compounds of Formula (I) is demonstrated by the following tests.
  • the murine bone marrow derived from stromal cell line C6.4 is grown in 12 well pates in RPMI 1640 with 10% FBS. Upon reaching confluence, the C6.4 cells are washed and the media exchanged with fresh RPMI 1640 without FBS. Confluent cell layers of murine C6.4 cells are treated with compound. Cell free supematants are collected 18 hours later. Supematants are fractionated with a Centricon-30 molecular weight cut-off membrane. C6.4 cell hematopoietic synergistic factor (HSF) activity is measured in a murine CFU-C assay.
  • HSF hematopoietic synergistic factor
  • Bone marrow cells are obtained from C57B1/6 female mice and suspended in RPMI 1640 with 10% FBS. Bone marrow cells (7.5E+4 cells/mL) are cultured with sub optimal levels of CFU plus dilutions of test C6.4 cell 30K-E supematants from above in a standard murine soft agar CFU-C assay. Cell aggregates >50 cells are counted as colonies. The number of agar colonies counted is proportional to the amount of HSF present within the C6.4 bone marrow stromal line supernatant.
  • mice Female C57B 1 mice are administered test compound PO daily for 8 days.
  • Resident peritoneal exudate cells (PEC) utilized ex vivo from treated or untreated mice are harvested with cold calcium and magnesium-free DPBS supplemented with heparin and antibiotics within 2-4 hours following the last injection.
  • Adherent PEM populations are prepared by incubating standardized PEC suspensions in microtiter dishes for 2 hours at 37 °C (5% CO2) and removing nonadherent cells by washing the wells with warm buffer.
  • SOD superoxide dismutase-inhibitable
  • nmoles of cytochrome c reduced /well is calculated from spectrophotometric readings (550 nm) taken following a 1 hour incubation at 37 °C (5% CO2).
  • the amount of SOD-inhibitable cytochrome c reduced is determined by the inclusion of wells containing SOD (200 U/well). Baseline superoxide release is determined in the absence of stimuli. Experimental data are expressed as a percentage of the control group.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Novel compounds of general formula (I) which have hemoregulatory activities and can be used to stimulate haematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.

Description

HEMOREGULATORY COMPOUNDS
Field of the Invention
The present invention relates to novel compounds which have hemoregulatory activities and can be used to stimulate haematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.
Background of the Invention
The haematopoietic system is a life-long cell renewal process whereby a defined stem cell population gives rise to a larger population of mature, differentiated blood cells (Dexter TM. Stem cells in normal growth and disease, Br Med J 1987; 195: 1 192-1 194) of at least nine different cell lineages (erythrocytes, platelets, eosinophils, basophils, neutrophils, monocytes/macrophages, osteoclastes and lymphocytes) (Metcalf D. The Molecular Control of Blood Cells, 1988; Harvard University Press, Cambridge, MA). The stem cells are also ultimately responsible for regenerating the bone marrow following treatment with cytotoxic agents or following bone marrow transplantation.
The major dose-limiting toxicities of most standard anti-neoplastic drugs are related to bone marrow suppression, which if severe and prolonged, can give rise to life- threatening infectious and haemorrhagic complications. Myelosuppression is predictable and has been reported to be dose-limiting in greater than 50% of single- agent Phase I trials cytotoxic compounds (Merrouche Y, Catimel G, Clavel M. Haematopoietic growth factors and chemoprotectants; should we move toward a two-step process for phase I trials in oncology? Ann Oncol 1993; 4:471-474). The risk of infection is directly related to the degree of myelosuppression as measured by the severity and duration of neutropenia (Brody GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infections with acute leukemia. Ann In Med 1965; 64:328-334). The control of haematopoiesis involves the interplay of a variety of cytokines and growth factors during various stages of the haematopoietic cascade, including early pluripotent stem cells and mature circulating effector cells. These regulator)' molecules include granulocyte colony stimulating factor (G-CSF), granulocyte- macrophage stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), and a variety of interleukines which have overlapping, additive and synergistic actions which play major roles in host defence. Mechanistically, this is accomplished by enhancing the production of granulocytes and macrophages, as well as by the activation of effector cell functions (Moore MAS. Haematopoietic growth factor interactions: in vitro and in vivo preclinical evaluation. Cancer Surveys 1990; 9:7-80). These co-ordinated activities support optimal host defences which are necessary for fighting bacterial, viral and fungal infections.
Strategies to prevent or reduce the severity of neutropenia and myelotoxicity include the use of haematopoietic growth factors and/or other haematopoietic cytokines. Such treatments are becoming common practice, in that they offer the potential of increased doses of cytotoxic agents that may improve the therapeutic efficacy in antineoplastic agents, and reduce the morbidity associated with their use (Steward WP. Granulocyte and granulocyte-macrophage colony stimulating factors, Lancet 1993; 342: 153-157). Clinical studies have demonstrated the G-, GM- and/or M-CSF may reduce the duration of neutropenia, accelerate myeloid recovery and reduce neutropenia-associated infections and other infectious complications in patients with malignancies who are receiving cytotoxic chemotherapy or in high infectious-risk patients following bone marrow transplantation (Steward WP. Granulocyte and granulocyte-macrophage colony stimulating factors, Lancet 1993; 342: 153-157 and Munn DH, Cheung NKV. Preclinical and clinical studies of macrophage colony- stimulating factor. Semin Oncol 1992; 19:395-407). We have now found certain novel compounds which have a stimulative effect on myelopoietic cells and are useful in the treatment and prevention of viral, fungal and bacterial diseases
Summary of the Invention
This invention comprises compounds, hereinafter represented as Formula (I), which have hemoregulatory activities and can be used to stimulate haematopoiesis and in the prevention and treatment of bacterial, viral and fungal diseases
These compounds are useful in the restoration of leukocytes in patients with lowered cell counts resulting from a variety of clinical situations, such as surgical induced myelosuppression, AIDS, ARDS, congenital myelodysplacis, bone marrow and organ transplants, in the protection of patients with leukopenia from infection, in the treatment of severely burned patients and in the amelioration of the myelosuppression observed with some cell-cycle specific antiviral agents and in the treatment of infections in patients who have had bone marrow transplants, especially those with graft versus host disease, in the treatment of tuberculosis and in the treatment of fevers of unknown origin in humans and animals The compounds are also useful in the treatment and prevention of viral, fungal and bacterial diseases, particularly Candida, Herpes and hepatitis in both immunosuppressed and "normal" subjects
These compounds may also be used in combination with the monomers of co- pending U.S Application No 07/799,465 and U.S Patent No 4,499,081, incoφorated by reference herein, to provide alternating peaks of high and low activity in the bone marrow cells, thus augmenting the natural circadian rhythm of haematopoiesis In this way, cytostatic therapy can be given at periods of low bone marrow activity, thus reducing the risk of bone marrow damage, while regeneration will be promoted by the succeeding peak of activity This invention is also a pharmaceutical composition, which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.
This invention further constitutes a method for stimulating the myelopoietic system of an animal, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).
This invention also constitutes a method for preventing and treating viral, fungal and bacterial infections including sepsis, in immunosuppressed and normal animals, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).
Detailed Description of the Invention
The compounds of the invention are represented by structural Formula I
Figure imgf000006_0001
wherein:
Aj equals A2 and denotes a group Z-(CH2)k-(NR"')q, wherein Z is a 4 - 10 membered mono- or bicyclic heterocyclic ring system containing up to four heteroatoms N, O, S in the ring in which at least one heteroatom is N, and wherein the ring is substituted or unsubstituted by one or two Cj^alkyl, F, Cl, Br, I, Cj.4 alkoxy, (CH2)mR4, oxo, oxime, O-C]_4alkyloxime, hydroxy, N(R )2, acylamino or aminoacyl groups, 8, 9, 10 membered monocyclic ring systems being excluded; R and R are the same and are independently hydrogen, Cj_4alkylC(O)R4, C\_ 4alkyl or R' and R" are benzyl which is optionally substituted by one or two Cj^alkyl, C] 4alkoxy, F, Cl, I, Br, OH, or N(R3)2; k is independently an integer from 0 to 4; R'" denotes Hydrogen, Cj^-alkyl or C \ _4-alkylcarboxylic acid; q is an integer from 0 to 1 ;
Q denotes a group
B,
B1 C1 wherein:
B\ equals B2 and denotes halogen, -(CH2)m-CN, -(CH2)m+l-R^. -(CH2 R3, -(CH2)m-COR2 or -(CH2)m-COR3; where R2 denotes - OR3, -N(R3)2, - SR3; R3 is independently hydrogen, Cι-C4-alkyl or benzyl; m is independently an integer from 0 to 4;
Ci equals C2 and denotes halogen, -(CH2)n-CN, -(CH2)n+l-R > -(CH2)n-R5, -(CH2)n-COR4 or -(CH2)n-COR5;
R4 independently denotes -OR5, -N(R5)2, - SR5; R5 independently is hydrogen, Cj-C4-alkyl or benzyl; n is independently an integer from 0 to 4;
D is (CH2)i, in which up to two carbons are optionally gem-substituted by R6 and R7; where
R6 and R7 are independently Cι _4alkyl, C2-4alkenyI, C2_4alkynyl; all of which may be substituted by one or two Cj^alkyl, OH, F, Cl, Br, I, N(Rg)2, (Rs)2 C(O)-, -(CH2)nR9, -(CH2)nR8, -(CH)2)nCOR9 or -(CH2)nC(0)R8; or R6 and R7are F, Cl, or Br; or R" and R7may together form a cyclic or heterocyclic ring of Formula (Ia): (CH2)p (CH2)q da)
in which p and q are independently an integer from 0 to3; provided p and q are not both 0;
X is O, S, CH2 or N(R8);
R8 is independently hydrogen, Cj_4-alkyl or benzyl;
R9 is independently OR8, N(R8)2 or SR8; i is an integer from 3 to 8; and with the proviso that B i is not identical to Cj and B2 is not identical to C2, and pharmaceutically acceptable salts thereof.
Z in the above Formula (I) denotes an optionally substituted pyrrolyl, isopyrrolyl, pyrazolyl, isoimidazolyl, triazolyl, iosxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, piperazinyl, triazinyl, morpholinyl, indolyl, indoleninyl, isobenzazolyi, pyrindinyl, ioindazolyl, indoxazinyl, benzoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, pyridopyridinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, indolinyl, pyrrolidonyl, imidazolyl, imidazolidinyl, imidazolinyl, piperidyl, tetrazolyl, quinuclidinyl, azetidinyl, or purinyl;
Possible substituents for Z are Cι _4-alkyl, Cj^-alkoxy, Cι_4-alkoxy-Cι_4-alkyl, oxo, oxime, O-Cj^-alkyloxime, hydroxy, amino, Cι_4-aIkylamino, di-Cj_4- alkylamino, acylamino and aminoacyl.
R3, as well as R5, denotes hydrogen, methyl, ethyl, propyl, i-propyl, butyl and benzyl. Preferred compounds are those wherein Z is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, tetrahydroquinolinyl, azetidinyl, or pyrrolidinyl; R^ and R are Cj_4alkyl, substituted by C 1.4 alkyl, OH, N(R8) 2, -(CH2)nR9, or -(CH2)nC(O)R8; or R6 and R7 may together form a cyclic or heterocyclic ring of Formula (Ia) wherein X is O, S, or CH2; and p and q are 1-3; R8 is hydrogen or C 1.4 alkyl; and R9 is OR8 or N(R )2-
More preferred compounds are those wherein Z is 2-pyridinyl, 2-pyrimidinyl, 2-pyrazinyl, 2-pyrrolidon-5-yl, or pyrrolidinyl; R6 and R7are Cj_2 alkyl, substituted by Cj^alkyl, OH, N(R )2, or -(CH2)n ; or R^ a°d R7 may together form a heterocyclic ring of Formula (Ia) wherein X is O; and p and q are 1 or 2; Rg is hydrogen or Cj.4a.kyl; and R9 is OR8, or
N(R8)2.
Preferred substituents for Z are methyl, ethyl, methoxy, methoxy methyl, oxo, oxime, hydroxy, amino, ethylamino or dimethylamino.
Preferred groups R' and R" are hydrogen, methyl and ethyl.
Alkyl groups may be straight or branched.
The compounds of the present invention may contain one ore more asymmetric carbon atoms and may exist in racemic and optically active forms. All the compounds and diastereomers are contemplated to be within the scope of the present compounds.
Methods of Preparation
Compounds of Formula (I) wherein R', R", R'", Cj, C2, B , B2, Aj, A , Z, k, m, n, x and y are defined as in Formula (I) are prepared by methods analogous to those described in Scheme 1. Compounds of Formula (I) wherein E, R', R", R'", Cj, C2, Bj, B2, Ai, A2, Z, k, m, n, x and y are defined as in Formula (I) are prepared by methods analogous to those described in Scheme 1.
Scheme 1
Figure imgf000010_0001
Figure imgf000011_0001
Figure imgf000011_0002
Figure imgf000011_0003
a) butyllithium, THF; b) cone. HCl, dioxane/ethanol; c) EDC, DMF; d) NaOH, dioxane/ethanol
(2S)-2,5-Dihydro-3,6-diethoxyisoproρylpyrazine (1 in Scheme 1) is coupled with an appropriate dielectrophile, such as 2 in Scheme 1, using a strong base (such as butyllithium) in a suitable solvent (such as THF) to give 3 in Scheme 1. Hydrolysis and ring-opening under standard acidic conditions (such as diluted HCl) in a suitable solvent (such as dioxane/ethanol) leads to a diamine, such as 4 in Scheme 1 , which is then bis-acylated with appropriate heterocyclic acids, such as 5_ in Scheme 1 , using an activating agent (such as EDC) in an aprotic polar solvent (such as DMF). Hydrolysis of the ester under standard basic conditions (such as NaOH) in a suitable solvent (such as dioxane/ethanol) furnishes the product 7 in Scheme 1. In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with pharmaceutical practice as a pharmaceutical composition.
According to a still further feature of the present invention there are provided pharmaceutical compositions comprising as active ingredient one or more compounds of Formula (I) as herein before defined or physiologically compatible salts thereof, in association with a pharmaceutical carrier or excipient. The compositions according to the invention may be presented for example, in a form suitable for oral, nasal, parenteral or rectal administration.
As used herein, the term "pharmaceutical" includes veterinary applications of the invention. These peptides may be encapsulated, tableted or prepared in an emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline and water. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies, but, preferably will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing and filling for hard gelatin capsule forms. Capsules containing one or several active ingredients may be produced, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and filling the mixture into gelatin capsules. Organ specific carrier systems may also be used.
Alternately pharmaceutical compositions of the peptides of this invention or derivatives thereof, may be formulated as solutions of lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation is generally a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration and contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxycellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
For rectal administration, a pulverized powder of the peptides of this invention may be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository. The pulverized powders may also be compounded with oily preparation, gel, cream or emulsion, buffered or unbuffered, and administered through a transdermal patch.
Nasal sprays may be formulated similarly in aqueous solution and packed into spray containers either with an aerosol propeilant or provided with means for manual compression.
Dosage units containing the compounds of this invention preferably contain 0.05-50 mg, for example 0.05-5 mg of the compound of Formula (I) or of the salt thereof.
According to a still further feature of the present invention there is provided a method of stimulation of myelopoiesis which comprises administering an effective amount of a pharmaceutical composition as hereinbefore defined to a subject. No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention. The biological activity of the compounds of Formula (I) is demonstrated by the following tests.
Induction of Hematopoietic Synergistic Activity in Stromal Cells
The murine bone marrow derived from stromal cell line C6.4 is grown in 12 well pates in RPMI 1640 with 10% FBS. Upon reaching confluence, the C6.4 cells are washed and the media exchanged with fresh RPMI 1640 without FBS. Confluent cell layers of murine C6.4 cells are treated with compound. Cell free supematants are collected 18 hours later. Supematants are fractionated with a Centricon-30 molecular weight cut-off membrane. C6.4 cell hematopoietic synergistic factor (HSF) activity is measured in a murine CFU-C assay.
CFU-C Assay
Bone marrow cells are obtained from C57B1/6 female mice and suspended in RPMI 1640 with 10% FBS. Bone marrow cells (7.5E+4 cells/mL) are cultured with sub optimal levels of CFU plus dilutions of test C6.4 cell 30K-E supematants from above in a standard murine soft agar CFU-C assay. Cell aggregates >50 cells are counted as colonies. The number of agar colonies counted is proportional to the amount of HSF present within the C6.4 bone marrow stromal line supernatant.
Effector Cell Function Assay
Female C57B 1 mice are administered test compound PO daily for 8 days. Resident peritoneal exudate cells (PEC) utilized ex vivo from treated or untreated mice are harvested with cold calcium and magnesium-free DPBS supplemented with heparin and antibiotics within 2-4 hours following the last injection. Adherent PEM populations are prepared by incubating standardized PEC suspensions in microtiter dishes for 2 hours at 37 °C (5% CO2) and removing nonadherent cells by washing the wells with warm buffer. The superoxide dismutase-inhibitable (SOD) superoxide released by effector cells in response to a in vitro stimulation by phorbol myristate acetate (PMA) (100-200 nM) or pre-opsonized (autologous sera) live C. albicans (E:T = 1 : 10) are quantitated in a microtiter ferricytochrome c reduction assay. The assay is performed in the presence of 1 % gelatin HBSS and 80 uM ferricytochrome c in a total volume of 200 μL/well. The nmoles of cytochrome c reduced /well is calculated from spectrophotometric readings (550 nm) taken following a 1 hour incubation at 37 °C (5% CO2). The amount of SOD-inhibitable cytochrome c reduced is determined by the inclusion of wells containing SOD (200 U/well). Baseline superoxide release is determined in the absence of stimuli. Experimental data are expressed as a percentage of the control group.

Claims

Claims:
Compounds of the formula (I):
Figure imgf000016_0001
wherein:
Aj equals A2 and denotes a group Z-(CH2)j -(NR'")q, wherein Z is a 4 - 10 membered mono- or bicyclic heterocyclic ring system containing up to four heteroatoms N, O, S in the ring in which at least one heteroatom is N, and wherein the ring is substituted or unsubstituted by one or two Cj^alkyl, F, Cl, Br, I, Cj_4 alkoxy, (CH2)mR4, oxo, oxime, O-Cj_4alkyloxime, hydroxy, N(R3)2, acylamino or aminoacyl groups, 8, 9, 10 membered monocyclic ring systems being excluded; R and R are the same and are hydrogen, Cj_4alkylC(O)R4, Cj .4 alkyl or R' and R" are benzyl which is optionally substituted by one or two C j_4alkyl, Cj_4alkoxy, F, Cl, I, Br, OH, or N(R3)2; k is independently an integer from 0 to 4; R'" denotes Hydrogen, Cj^-alkyl or Cj_4-alkylcarboxylic acid; q is an integer from 0 to 1 ;
Q denotes a group
Figure imgf000016_0002
B1 C1 wherein:
B j equals B2 and denotes halogen, -(CH2)m-CN, -(CH2)m+l- 2, -(CH2)m-R , -(CH2)m-COR2 or -(CH2)m-COR3;
R2 denotes - OR3, -N(R3)2, - SR3;
R3 is independently hydrogen, Cj-C4-alkyl or benzyl; m is independently an integer from 0 to 4; C j equals C2 and denotes halogen, -(CH2)n-CN, -(CH2)n+ 1 -R4,
-(CH2)n-R5, -(CH2)n-COR4 or -(CH2)n-COR5;
R4 independently denotes -OR5, -N(R5)2, - SR5;
R5 independently is hydrogen, C -C4-alkyl or benzyl; n is independently an integer from 0 to 4; D is (CH2) , in which up to two carbons are optionally gem-substituted by
R6 and R7; where
R6 and R7 are independently Cj^alkyl, C2-4alkenyl, C2-4alkynyl; all of which may be substituted by one or two Cj. alkyl, OH, F, Cl, Br, I, N(R8) , (R8)2NC(O)-, -(CH2)n 9. -(CH2)nR8, -(CH)2)nCOR9, or -(CH2)nC(O)R8; or R6 and R7 are F, Cl, or Br; or R6 and R7 may together form a cyclic or heterocyclic ring of Formula (Ia):
(CH2)p (CH2)q
\ / (Ia)
in which p and q are independently an integer from 0 to3; provided p and q anre not both 0; X is O, S, CH2 or N(R8);
R8 is independently hydrogen, Cj.4-alkyl or benzyl; R9 is independently OR8, N(R8)2 or SR8; i is an integer from 3 to 8;
and with the proviso that Bj is not identical to Cj and B2 is not identical to C2, and pharmaceutically acceptable salts thereof.
-15-
SUBSTITUTΈ SHEET (RULE 26)
2. Compounds according to claim 1, wherein Z is an optionally substituted pyrrolyl, isopyrrolyl, pyrazolyl, isoimidazolyl, triazolyl, iosxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, piperazinyl, triazinyl, morpholinyl, indolyl, indoleninyl, isobenzazolyi, pyrindinyl, ioindazolyl, indoxazinyl, benzoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, pyridopyridinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, indolinyl, pyrrolidonyl, imidazolyl, imidazolidinyl, imidazolinyl, piperidyl, tetrazolyl, quinuclidinyl, azetidinyl, or purinyl.
3. Compounds according to claim 1, wherein Z is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, tetrahydroquinolinyl, azetidinyl, or pyrrolidinyl; R6 and R7 are Cj^alkyl, substituted by Cj.4 alkyl, OH, N(R8) 2, - (CH )nR9, or -(CH2)nC(O)R8; or R6 and R7 may together form a cyclic or heterocyclic ring of Formula (Ia) wherein X is O, S, or CH2; and p and q are 1-3; R8 is hydrogen or C j_4alkyl; and R9 is OR8 or N(R8)2.
4. Compounds according to claim 1 wherein Z is optionally mono-, poly- or mixed substituted by Cj_4-alkyl, Cj_4-alkoxy, Cι_4-alkoxy-Cι.4-alkyl, oxo, oxime, O-C _4-alkyloxime, hydroxy, amino, Cj_4-alkylamino, di-Cj_4- alkylamino, aminoacyl or acylamino.
5. Compounds according to claim 1 wherein Z is optionally mono-, poly- or mixed substituted by methyl, ethyl, methoxy, methoxymethyl, oxo, oxime, hydroxy, amino, ethylamino or dimethylamino.
6. Compounds according to claim 1 wherein R' and R" are equal and denote hydrogen, methyl, ethyl, propyl, butyl, Cj^-alkylcarboxylic acid or C2-4-alkylhydroxy.
7. Compounds according to claim 1 wherein B j and B2 and denotes halogen, -(CH2)m-CN, -(CH2)m+j-R2, -(CH2)m-R3, -(CH2)m-COR2 or -(CH2)m- COR3, where R2 denotes -OR3, -NR32, - SR3, and R3 is hydrogen, methyl, ethyl, propyl, i-propyl, butyl or benzyl and m is an integer from 0 to 4.
8. Compounds according to claim 1 wherein C equals C2 and denotes halogen, -(CH2)n-CN, -(CH2)n+ι-R4, -(CH2)n-R5, -(CH2)n-COR4 or -(CH2)n- COR5, where R4 denotes -OR5, -NR5 2, -SR5, and R5 is hydrogen, methyl, ethyl, propyl, i-propyl, butyl or benzyl and n is an integer from 0 to 4.
9. A pharmaceutical composition comprising a compound according to claims 1 and a pharmaceutically acceptable carrier.
10. A method of stimulating the myelopoietic system which comprises administering to a subject in need thereof, an effective amount to stimulate said myelopoietic system of a compound to claim 1.
11. A method of preventing or treating sepsis which comprises administering to a subject in need thereof, an effective amount of a compound of claim 1.
12. A method of preventing or treating viral, fungal and bacterial infections which comprises administering to a subject in need thereof, an effective amount of a compound of Claim 1.
PCT/US1996/018250 1995-11-13 1996-11-12 Hemoregulatory compounds WO1997017966A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9519064A JP2000502049A (en) 1995-11-13 1996-11-12 Blood regulatory compounds
EP96940440A EP0877611A4 (en) 1995-11-13 1996-11-12 Hemoregulatory compounds
US09/068,640 US6077856A (en) 1995-11-13 1996-11-12 Hemoregulatory compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US660795P 1995-11-13 1995-11-13
US60/006,607 1995-11-13

Publications (1)

Publication Number Publication Date
WO1997017966A1 true WO1997017966A1 (en) 1997-05-22

Family

ID=21721699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/018250 WO1997017966A1 (en) 1995-11-13 1996-11-12 Hemoregulatory compounds

Country Status (5)

Country Link
US (1) US6077856A (en)
EP (1) EP0877611A4 (en)
JP (1) JP2000502049A (en)
HU (1) HUP9902082A3 (en)
WO (1) WO1997017966A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0861080A1 (en) * 1995-11-13 1998-09-02 Smithkline Beecham Corporation Hemoregulatory compounds

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917626A (en) * 1971-03-29 1975-11-04 Ici Ltd 3,6-Dioxa-1,8-octandiamido bis (pyridinium) compounds
US5360806A (en) * 1992-07-23 1994-11-01 Ishihara Sangyo Kaisha Ltd. Amide compounds and their salts and pesticidal compositions containing them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0701446A4 (en) * 1993-05-24 1997-04-23 Smithkline Beecham Corp Hemoregulatory peptides
JP2000501385A (en) * 1995-11-13 2000-02-08 スミスクライン・ビーチャム・コーポレイション Blood regulatory compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917626A (en) * 1971-03-29 1975-11-04 Ici Ltd 3,6-Dioxa-1,8-octandiamido bis (pyridinium) compounds
US5360806A (en) * 1992-07-23 1994-11-01 Ishihara Sangyo Kaisha Ltd. Amide compounds and their salts and pesticidal compositions containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0877611A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0861080A1 (en) * 1995-11-13 1998-09-02 Smithkline Beecham Corporation Hemoregulatory compounds
EP0861080A4 (en) * 1995-11-13 1999-01-20 Smithkline Beecham Corp Hemoregulatory compounds

Also Published As

Publication number Publication date
EP0877611A4 (en) 1999-02-17
US6077856A (en) 2000-06-20
EP0877611A1 (en) 1998-11-18
HUP9902082A3 (en) 2001-10-29
HUP9902082A2 (en) 1999-10-28
JP2000502049A (en) 2000-02-22

Similar Documents

Publication Publication Date Title
US6077857A (en) Hemoregulatory compounds
US6194413B1 (en) Hemoregulatory compounds
US6200986B1 (en) Hemoregulatory compounds
US6191146B1 (en) Hemoregulatory compounds
US6197793B1 (en) Hemoregulatory compounds
US6077855A (en) Hemoregulatory compounds
US6114357A (en) Hemoregulatory compounds
US6077856A (en) Hemoregulatory compounds
US6030989A (en) Hemoregulatory compounds
EP0874638A1 (en) Hemoregulatory compounds
US6051584A (en) Hemoregulatory compounds
US6054465A (en) Hemoregulatory compounds
US6046198A (en) Hemoregulatory compounds
US6046197A (en) Hemoregulatory compounds
US6107309A (en) Hemoregulatory compounds
EP0861077B1 (en) Hemoregulatory compounds
WO1997017963A1 (en) Hemoregulatory compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 519064

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996940440

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996940440

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09068640

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1996940440

Country of ref document: EP